Hepatocellular Carcinoma Clinical Trials in Harbin, Heilongjiang
7 recruitingHarbin, Heilongjiang, China
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled19 locationsNCT06427941
Recruiting
Phase 1
First in Human Study of SIM0610 in Solid Tumors
Colorectal, CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more
Jiangsu Simcere Pharmaceutical Co., Ltd.260 enrolled7 locationsNCT07348211
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
NWRD06 DNA Plasmid for HCC After Curative Resection.
Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.30 enrolled6 locationsNCT07324304
Recruiting
Phase 2
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.72 enrolled12 locationsNCT06954467
Recruiting
Phase 1
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
AbbVie20 enrolled11 locationsNCT06487559
Recruiting
Phase 3
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.480 enrolled67 locationsNCT05862337